Vanderbilt Ingram Cancer Center

Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology.

Distinct cancer-associated fibroblasts in the prostate tumor microenvironment may influence tumor progression and could point to new therapeutic targets.

Christine Lovly, MD, PhD, associate professor of Medicine in the Division of Hematology and Oncology and Ingram Professor of Cancer Research, is one of two inaugural recipients of the EGFR Resisters/LUNGevity Lung Cancer Research Award.

A study by Vanderbilt researchers that analyzed both smoking history and genetic risk variants for lung cancer supports modifying current guidelines to include additional smokers for lung cancer screening.

Vanderbilt researchers clarify how a microRNA associated with triple-negative breast cancer survival inhibits cancer progression, suggesting new treatment strategies.

When people go to an emergency room after being injured, suspicious images may show up on their imaging scans that are unrelated to their injuries but may be indicative of cancer. A team at Vanderbilt University Medical Center recently established a better process for ensuring these patients receive follow-up diagnostic care, an initiative that is already receiving national recognition.

A new method speeds the analysis of factors that control gene expression from days to minutes, allowing researchers to uncover new targets for cancer treatment.